Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
BerGenBio ASA
Pfizer
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Incyte Corporation
INSYS Therapeutics Inc